LEXICON PHARMACEUTICALS

Company snapshot

LEXICON PHARMACEUTICALS maintains 51 tracked programs across Type 2 Diabetes Mellitus, Irritable Bowel Syndrome, Rheumatoid Arthritis, Carcinoid Syndrome, Drug Interactions, Type 1 Diabetes Mellitus, Hepatic Impairment, Heart Failure, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Age-Related Memory Disorders, Primary Open-angle Glaucoma, Diabetic Peripheral Neuropathy. Momentum score: 2

• 2 approved product(s) across US/EU regulatory metadata.
• 51 active pipeline program(s) linked via ClinicalTrials.gov.
• 102 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for LEXICON PHARMACEUTICALS. Not investment advice.

• Peer + 0 momentum

  Sanofi Pasteur MSD

  TA overlap score 36.6

• Peer + 0 momentum

  AbbVie

  TA overlap score 28.2

Recent activity

Latest pipeline, patent, and corporate events for LEXICON PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN — Phase 3

2. Jun 8, 2026 Clinical update

   Treatment A digoxin — Phase 1

3. Jun 8, 2026 Clinical update

   Telotristat Ethyl — Phase 1

4. Jun 8, 2026 Clinical update

   Sotagliflozin (SOTA) followed by 3 drugs in a random order — Phase 1

5. Jun 8, 2026 Clinical update

   Sotagliflozin Low Dose — Phase 3

View all clinical trial activity →

• What is LEXICON PHARMACEUTICALS?

  Lexicon Pharmaceuticals is a pharma organization headquartered in The Woodlands, USA. It trades on NYSE under ticker LXRX. Primary therapeutic focus areas include Type 2 Diabetes Mellitus, Irritable Bowel Syndrome, Rheumatoid Arthritis, Carcinoid Syndrome, Drug Interactions. Nova

• Is LEXICON PHARMACEUTICALS publicly traded?

  Yes. LEXICON PHARMACEUTICALS is listed with ticker LXRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does LEXICON PHARMACEUTICALS develop or market?

  We link 27 drug profile(s) where LEXICON PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc#company-drugs.

• What are the latest developments for LEXICON PHARMACEUTICALS?

  In the last 12 months our linked public records show 51 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does LEXICON PHARMACEUTICALS focus on?

  LEXICON PHARMACEUTICALS focuses on Type 2 Diabetes Mellitus, Irritable Bowel Syndrome, Rheumatoid Arthritis based on our analysis of their pipeline programs and drug development activities.